[1]杨宇馨,何乐,卢先锋,等.血清APE1蛋白在结直肠癌临床诊断中的作用及意义[J].第三军医大学学报,2020,42(01):88-93.
 YANG Yuxin,HE Le,LU Xianfeng,et al.Diagnostic value and significance of serum APE1 in colorectal cancer[J].J Third Mil Med Univ,2020,42(01):88-93.
点击复制

血清APE1蛋白在结直肠癌临床诊断中的作用及意义(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第01期
页码:
88-93
栏目:
临床医学
出版日期:
2020-01-15

文章信息/Info

Title:
Diagnostic value and significance of serum APE1 in colorectal cancer
作者:
杨宇馨何乐卢先锋杨骁仲召阳王东戴楠
陆军军医大学(第三军医大学)大坪医院肿瘤中心
Author(s):
YANG Yuxin HE Le LU Xianfeng YANG Xiao ZHONG Zhaoyang WANG Dong DAI Nan

Cancer Center, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China

关键词:
APE1结直肠癌肿瘤标志物诊断
Keywords:
apurinic/apyrimidinic endonuclease 1 colorectal cancer tumor biomarker diagnosis  
分类号:
R341;R730.43;R735.35
文献标志码:
A
摘要:

目的探讨结直肠癌患者血清APE1蛋白的表达及其在临床诊断中的价值。方法利用ELISA法检测本院2010年1月至2015年9月肿瘤中心收治的202例结直肠癌患者和健康体检中心242例健康对照人群血清APE1蛋白的表达水平,通过免疫组化确定相应患者肿瘤组织APE1蛋白的表达特征,同时采用C-12肿瘤蛋白芯片试剂盒检测上述人群CEA的表达水平。分析血清APE1蛋白与肿瘤组织APE1蛋白表达水平及年龄、性别、分期等临床指标的相关性,并绘制受试者工作特征曲线(receiver operating characteristic curve,ROC)评估血清APE1蛋白及CEA在结直肠癌诊断中的应用价值。结果202例结直肠癌患者中位血清APE1蛋白浓度为0.331(0.007~4.359)ng/mL,显著高于对照组0.091(0~1.374)ng/mL(P<0.01)。Spearman相关分析显示血清APE1蛋白水平与肿瘤组织中APE1蛋白表达呈正相关(r=0.331,P=0.025),而与年龄、性别、分期等指标不相关。ROC曲线显示血清APE1蛋白的AUC为0.799(95%CI=0.756~0.843),灵敏度为76.20%,特异性为76.40%,血清CEA的AUC为0.736(95%CI=0.687~0.785),其灵敏度为51.00%,特异性为99.60%。血清APE1蛋白与CEA联合后其AUC为0.857(95%CI=0.819~0.896),灵敏度和特异性分别为72.30% 和91.30%。结论结直肠癌患者血清APE1蛋白水平与肿瘤组织APE1表达呈正相关且较健康对照人群显著增高。血清APE1蛋白可与CEA联合作为结直肠癌辅助诊断的血清学标志物。

Abstract:

ObjectiveTo investigate the expression of serum apurinic/apyrimidinic endonuclease 1 (APE1) in colorectal cancer and its diagnostic value. MethodsA total of 202 patients with identified colorectal cancer admitted in our center from January 2010 to September 2015 were recruited in this study, and another 242 healthy volunteers who took physical examination at the same period served as normal control. Their serum APE1 level was quantified by ELISA. The expression of APE1 protein in colorectal cancer tissues was detected by immunohistochemistry. The expression of carcinoembryonic antigen (CEA) was detected by C-12 tumor protein chip kit. The correlations of APE1 protein levels in the serum and tumor tissues with age, gender, clinical stage and other indicators were analyzed. Receiver operating characteristic (ROC) curve was plotted to evaluate the value of serum APE1 and CEA levels in the diagnosis of colorectal cancer. ResultsThe serum APE1 level was 0.331 (0.007~4.359) ng/mL in the colorectal cancer patients, which was significantly higher than that in healthy control [0.091(0~1.374) ng/mL, P<0.001]. Spearman correlation analysis showed that the serum APE1 level was positively correlated with its protein expression in colorectal cancer tissues (r=0.331, P=0.025), but had no relations with age, sex and clinical stages. ROC curve displayed that the area under the curve (AUC) was 0.799 (95%CI=0.756~0.843), the sensitivity was 76.20%, and the specificity was 76.40% for serum APE1 level in the diagnosis. While, the AUC value was 0.736 (95%CI=0.687~0.785), the sensitivity was 51.00%, and the specificity was 99.60% for serum CEA level. Their combination increased the AUC value to 0.857 (95%CI=0.819~0.896), and the sensitivity and accuracy to 72.30% and 91.30%, respectively. ConclusionThe serum APE1 level is positively correlated with its expression level in the colorectal cancer tissue, and both are significantly higher than those in the health control. Combined detection of serum APE1 and CEA levels might be considered as serum markers in auxiliary diagnosis for colorectal cancer.

参考文献/References:

[1]SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI:10.3322/caac.21551.
[2]CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI:10.3322/caac.21338.
[3]CHEN W Q, SUN K X, ZHENG R S, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1): 1-12. DOI:10.21147/j.issn.1000-9604.2018.01.01.
[4]DE MAIO G, RENGUCCI C, ZOLI W, et al. Circulating and stool nucleic acid analysis for colorectal cancer diagnosis[J]. World J Gastroenterol, 2014, 20(4): 957-967. DOI:10.3748/wjg.v20.i4.957.
[5]LI M X, WILSON D M 3rd. Human apurinic/apyrimidinic endonuclease 1[J]. Antioxid Redox Signal, 2014, 20(4): 678-707. DOI:10.1089/ars.2013.5492.
[6]KELLEY M R, GEORGIADIS M M, FISHEL M L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1[J]. Curr Mol Pharmacol, 2012, 5(1): 36-53. DOI: 10. 2174/1874- 470211205010036.
[7]TELL G, FANTINI D, QUADRIFOGLIO F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment[J]. Cell Mol Life Sci, 2010, 67(21): 3589-3608. DOI:10.1007/s00018-010-0486-4.
[8]DAI N, CAO X J, LI M X, et al. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer[J]. PLoS ONE, 2013, 8(3): e58001. DOI:10.1371/journal.pone.0058001.
[9]何乐, 杨宇馨, 张诗珩, 等. 血清APE1自身抗体在结直肠癌诊断中的价值[J]. 第三军医大学学报, 2016, 38(11): 1297-1301. DOI:10.16016/j.1000-5404.201601165.
HE L, YANG Y X, ZHANG S H, et al. Diagnostic value of serum APE1 autoantibodies in colorectal cancer[J]. J Third Mil Med Univ, 2016, 38(11): 1297-1301. DOI:10.16016/j.1000-5404.201601165.
[10]ZHANG S H, HE L, DAI N, et al. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients[J]. Oncotarget, 2016, 7(47): 77482-77494. DOI:10.18632/oncotarget.13030.
[11]GORGOULIS V G, VASSILIOU L V, KARAKAIDOS P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions[J]. Nature, 2005, 434(7035): 907-913. DOI:10.1038/nature03485.
[12]LI Z, QING Y, GUAN W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74(4): 777-786. DOI:10.1007/s00280-014-2562-1.
[13]CHOI S, JOO H K, JEON B H. Dynamic regulation of APE1/ref-1 as a therapeutic target protein[J]. Chonnam Med J, 2016, 52(2): 75-80. DOI:10.4068/cmj.2016.52.2.75.
[14]向德兵, 牟江洪, 谢家印, 等. 大肠癌APE1的表达特点及临床意义[J]. 解放军医学杂志, 2006, 31(2): 115-116. DOI: 10.3321/j.issn:0577-7402.2006.02.011.
XIANG D B, MOU J H, XIE J Y, et al. Expression feature of APE1 and its clinical implication in colorectal carcinoma[J]. Med J Chin PLA, 2006, 31(2): 115-116. DOI: 10.3321/j.issn:0577-7402.2006.02.011.
[15]XIANG D B, CHEN Z T, WANG D, et al. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo[J]. Cancer Gene Ther, 2008, 15(10): 625-635. DOI:10.1038/cgt.2008.30.
[16]LAI C Y, HSIEH L L, TANG R, et al. Association between polymorphisms of APE1 and OGG1 and risk of colorectal cancer in Taiwan[J]. World J Gastroenterol, 2016, 22(12): 3372-3380. DOI:10.3748/wjg.v22.i12.3372.
[17]SHIN J H, CHOI S, LEE Y R, et al. APE1/ref-1 as a serological biomarker for the detection of bladder cancer[J]. Cancer Res Treat, 2015, 47(4): 823-833. DOI:10.4143/crt.2014.074.
[18]PASCUT D, SUKOWATI C H C, ANTONIALI G, et al. Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma[J]. Oncotarget, 2019, 10(3): 383-394. DOI:10.18632/oncotarget.26555.
[19]HUAJUN W, YING F, HONGXING Z, et al. Clinical value of combined detection of serum APE1-Aabs and CEACAM-1 in the diagnosis of colorectal cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(5): 1286-1289. DOI:10.26355/eurrev_201803_14469.
[20]陈虞梅, 黄钢. 肿瘤标志物CEA, CA50和CA19-9在大肠癌诊断中的意义[J]. 放射免疫学杂志, 2005, 18(1): 8-10.
CHEN Y M, HUANG G. Diagnostic significance of tumor markers CEA, CA50 and CA19-9 for colorectal cancer[J]. J Radioimmunol, 2005, 18(1): 8-10.
[21]FAKIH M G, PADMANABHAN A. CEA monitoring in colorectal cancer. What you should know[J]. Oncology(Williston Park), 2006, 20(6):579-587.

相似文献/References:

[1]邵新宏,于游,张才全.miR-34a靶向调控NOTCH1基因对SW480细胞增殖的影响[J].第三军医大学学报,2012,34(22):2297.
 Shao Xinhong,Yu You,Zhang Caiquan.Inhibitory effects of miR-34a on NOTCH1 gene expression and SW480 cell proliferation[J].J Third Mil Med Univ,2012,34(01):2297.
[2]王祥峰,张连阳,何渝军,等.结直肠癌患者血清及粪便中热休克蛋白60检测的临床意义[J].第三军医大学学报,2007,29(13):1334.
 WANG Xiang-feng,ZHANG Lian-yang,HE Yu-jun,et al.Clinical significance of HSP60 in serum and stool of colorectal cancer patients[J].J Third Mil Med Univ,2007,29(01):1334.
[3]陈曦,黄悦,于彬,等.结直肠癌单克隆抗体的制备及生物学特性鉴定[J].第三军医大学学报,2007,29(10):896.
 CHEN Xi,HUANG Yue,YU Bin,et al.Preparing and identifying a monoclonal antibody against human colorectal carcinoma[J].J Third Mil Med Univ,2007,29(01):896.
[4]甘露,张超,曾冬竹,等.结直肠癌患者腹腔镜手术与开腹手术后并发症的风险因素分析[J].第三军医大学学报,2008,30(17):1668.
 GAN Lu,ZHANG Chao,ZENG Dong-zhu,et al.Laparoscopic-assisted versus open colorectal surgery: risk factor analysis for postoperative complications[J].J Third Mil Med Univ,2008,30(01):1668.
[5]赵菲,李世拥,于波,等.青年与老年结直肠癌临床病理特征的对比分析[J].第三军医大学学报,2007,29(06):544.
 ZHAO Fei,LI Shi-yong,YU Bo,et al.Comparative study on clinical pathological characteristics of young and old patients with colorectal cancer[J].J Third Mil Med Univ,2007,29(01):544.
[6]马千里,马华,陈曦,等.C-KIT蛋白在结直肠癌中的表达及临床意义[J].第三军医大学学报,2006,28(08):830.
[7]梁后杰,赵晓昕.结直肠癌肝转移新辅助化疗的共识与争议[J].第三军医大学学报,2009,31(01):26.
[8]马恒太,余佩武,葛海燕,等.体力活动对结直肠癌发病影响的重庆地区大样本病例-对照研究[J].第三军医大学学报,2005,27(22):2276.
[9]温玉婷,刘伟,杨爱军,等.IL-17和STAT3在结直肠癌组织中的表达及临床意义[J].第三军医大学学报,2011,33(17):1812.
 Wen Yuting,Liu Wei,Yang Aijun,et al.Expression of IL-17 and STAT3 in colorectal cancer tissue and its clinical significance[J].J Third Mil Med Univ,2011,33(01):1812.
[10]李靓,李洋,王继见.hTR反义寡核苷酸对结直肠癌SW480细胞的凋亡及凋亡诱导因子表达的影响[J].第三军医大学学报,2010,32(22):2400.
 Li Liang,Li Yang,Wang Jijian.Effect of hTR antisense oligodeoxynucleotide on apoptosis and expressions of apoptosis inducing factor in colon carcinoma cells SW480[J].J Third Mil Med Univ,2010,32(01):2400.

更新日期/Last Update: 2020-01-07